Charles Bankhead is a Staff Writer at MedPage Today. He covers a range of topics within medicine and healthcare, including oncology, immunotherapy, gene therapy, and mental health care, while also exploring themes of wellness and alternative medicine. His work has been featured in Knowledia, MDEdge, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Charles Bankhead's focus is primarily on medical research, clinical trials, FDA approvals, and scientific developments in healthcare and pharmaceuticals. His coverage includes citing data from various studies and press releases.
If you are reaching out to Charles, consider providing insights or commentary based on recent medical research findings or clinical trial outcomes. Expert opinions related to FDA approvals, drug therapies, or challenges in specific areas of healthcare could be well-received by him.
Since his geographic focus is not specified but his topics are broad and universal, pitches can come from experts across the globe who have valuable insights into these areas of medical research and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The FDA approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), Outlook Therapeutics announced on Friday.
By: Charles Bankhead
News, features, and commentary about cancer-related issues
Many pieces of circumstantial evidence, but definitive proof remains elusive
By: Charles Bankhead
Key Takeaways A peptide vaccine targeting KRAS mutations in patients at high risk for pancreatic cancer induced durable T-cell responses.
In 1976, German virologist Harald zur Hausen, MD, DSc, proposed that human papillomavirus (HPV) causes cervical cancer, countering the widely held belief that herpes simplex virus caused the cancer.
Key Takeaways Ocular adverse effects have been reported among users of PDE5 inhibitors, including rare but serious events such as retinal detachment, retinal vascular occlusion, and ischemic optic neuropathy.
— No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years
By: Charles Bankhead
People who had restricted sugar exposure opens in a new tab or window during the first 2 years of life grew into adults with a lower risk of cancer. ( American Journal of Clinical Nutrition
By: Charles Bankhead
2% risk with one worrisome or high-risk feature, but risk rises to 18% with three or more traits
By: Charles Bankhead
An accumulation of worrisome or high-risk traits in pancreatic cysts increased the likelihood of a subsequent pancreatic cancer diagnosis, a prospective single-center study of more than 200 patients showed.
